FreeStyle

Tandem Diabetes Care’s t:slim X2™ Insulin Pump is the First Automated Insulin Delivery System to Integrate with Abbott’s New FreeStyle Libre® 2 Plus Sensor

Retrieved on: 
Monday, January 8, 2024
Wearables, Mobile Technology, Technology, Mobile, Wireless, Medical Devices, Diabetes, Health Technology, Software, Biotechnology, Health, Continuous glucose monitor, Personal, Multimedia, CGM, Caregiver, DME, AID, Disease, Hyperglycemia, Internet, Tandem Diabetes Care, Control, FreeStyle, Medical device

(NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that the t:slim X2 insulin pump with Control-IQ technology is the first automated insulin delivery (AID) system to integrate with the newly available FreeStyle Libre 2 Plus sensor, Abbott’s latest continuous glucose monitoring (CGM) technology.

Key Points: 
  • (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that the t:slim X2 insulin pump with Control-IQ technology is the first automated insulin delivery (AID) system to integrate with the newly available FreeStyle Libre 2 Plus sensor, Abbott’s latest continuous glucose monitoring (CGM) technology.
  • View the full release here: https://www.businesswire.com/news/home/20240108667517/en/
    t:slim X2 Insulin Pump from Tandem Diabetes Care with Abbott’s Freestyle Libre 2 Plus sensor integration now available in the United States.
  • (Photo: Business Wire)
    Tandem’s t:slim X2 insulin pump connects wirelessly to the FreeStyle Libre 2 Plus sensor, which sends automatic glucose readings every minute2,3 to the pump.
  • FreeStyle Libre 2 Plus sensor connects via Bluetooth to the Tandem t:slim X2 insulin pump.

$26.89 Bn Wearable Patches Markets - Global and Regional Analysis Report 2023-2031 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 7, 2023
Medical Devices, Health, Technology, Wearables, Mobile Technology, Pharmaceutical, Biotechnology, ECG, Migraine, Nursing, T1D, Abbott Laboratories, Food, Prevalence, Ageing, AID, MDR, Laboratory, Continuous glucose monitor, FDA, Heart rate, Region, CE, Conditional sentence, Clothing, Software, Diagnosis, Communication, Growth, Medicare, Hyperglycemia, FreeStyle, Hospital, Skin, Continuous monitoring, Diabetes, Stroke, GlySens ICGM, Temperature, Hypoglycemia, Blood pressure, Medical device, Pharmaceutical industry

The "Wearable Patches Market - A Global and Regional Analysis: Focus on Usage Type, Application, End User, and Region - Analysis and Forecast, 2023-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Wearable Patches Market - A Global and Regional Analysis: Focus on Usage Type, Application, End User, and Region - Analysis and Forecast, 2023-2031" report has been added to ResearchAndMarkets.com's offering.
  • The key factors driving the growth of the global wearable patches market include continuous monitoring of body vitals and minimum interference with body movement, increasing prevalence of chronic disorders (diabetes, strokes, etc.
  • The top segment players who are leading include manufacturers of different kinds of wearable medical patches.
  • Patches such as blood glucose patches, heart rate and ECG patches, temperature patches, and others are used for monitoring and diagnosis of various conditions.

Global Wearable Patches Market Analysis Report 2023: Market to Exceed $26.8 Billion by 2031 - AI Algorithms for Wearable Patches for Better Clinical Outcome Presents Unique Opportunities

Retrieved on: 
Friday, December 8, 2023
ECG, Migraine, Nursing, T1D, Abbott Laboratories, Food, Prevalence, Ageing, AID, MDR, Laboratory, Stroke, Continuous glucose monitor, FDA, Heart rate, Region, CE, Conditional sentence, Clothing, Diabetes, Software, Diagnosis, Communication, Growth, Medicare, Hyperglycemia, FreeStyle, Hospital, Skin, Continuous monitoring, GlySens ICGM, Temperature, Hypoglycemia, Blood pressure, Beauty salon, Medical device, Pharmaceutical industry

The global wearable patches market was valued at $10,462.4 million in 2022 and is expected to reach $26,892.7 million by 2031, growing at a CAGR of 10.19% between 2023 and 2031.

Key Points: 
  • The global wearable patches market was valued at $10,462.4 million in 2022 and is expected to reach $26,892.7 million by 2031, growing at a CAGR of 10.19% between 2023 and 2031.
  • The top segment players who are leading include manufacturers of different kinds of wearable medical patches.
  • The blood glucose patches captured around 82.23% of the presence in the market in 2022.
  • Patches such as blood glucose patches, heart rate and ECG patches, temperature patches, and others are used for monitoring and diagnosis of various conditions.

Abbott and WeightWatchers Connected App Experience is Now Available for People Living with Diabetes

Retrieved on: 
Tuesday, September 19, 2023
CGM, Partnership, Food, Type 2 diabetes, WW International, Diabetes, FreeStyle, Glucose, Risk, WW, A1C, Type 2, Love, Korea Disease Control and Prevention Agency, Health, NYSE, Dietary supplement

ABBOTT PARK, Ill. and NEW YORK, Sept. 19, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) and WW International, Inc. (NASDAQ: WW), known as WeightWatchers, announced today the availability of a connected app to help people living with diabetes understand how food and activity impact their glucose levels.

Key Points: 
  • ABBOTT PARK, Ill. and NEW YORK, Sept. 19, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) and WW International, Inc. (NASDAQ: WW), known as WeightWatchers, announced today the availability of a connected app to help people living with diabetes understand how food and activity impact their glucose levels.
  • Type 2 diabetes is on the rise, and according to the Centers for Disease Control and Prevention , more than 37 million Americans have diabetes and approximately 90 percent of those people have Type 2 diabetes 7.
  • Some of the risk factors for Type 2 diabetes include lifestyle decisions that pertain to food, activity, and weight.
  • To sign up for each of these offers and to learn more about the connected app experience, visit ww.com/diabetesconnection .

GoodRx Surpasses $500 Million in Savings For Diabetic Americans

Retrieved on: 
Tuesday, August 15, 2023
Software, Pharmaceutical, Internet, General Health, Health, Diabetes, Technology, Apps, Applications, FreeStyle, GoodRx, Prescription, Continuous glucose monitor, Dexcom, Pharmacist, G6, MD, Patient, Physician, Gold, Pharmaceutical industry, Health insurance

While cost is a significant barrier to diabetes patients accessing the care they need, a lack of clear, concise information about treatment plans can be a barrier as well.

Key Points: 
  • While cost is a significant barrier to diabetes patients accessing the care they need, a lack of clear, concise information about treatment plans can be a barrier as well.
  • The GoodRx Health Diabetes Center provides information about treatments, medications, common concerns, and more that is credible and up-to-date to support readers with actionable next steps for managing their condition.
  • “By providing incredible savings and information in one place, GoodRx is an invaluable resource for those living with diabetes to help them more easily access and afford the proper treatment they need.”
    To find savings and trusted health information, download the GoodRx app or go to www.goodrx.com .
  • For even greater savings on your prescriptions, try GoodRx Gold .

Abbott's FreeStyle Libre® Continuous Glucose Monitoring Systems Obtain Significantly Expanded Coverage for Medicare Beneficiaries

Retrieved on: 
Monday, April 17, 2023
CGM, Regulation of tobacco by the U.S. Food and Drug Administration, Insulin, Prevalence, Diabetes, FreeStyle, Abbott, Continuous glucose monitor, History, Medicare, Dizziness, Patient, Himawari (satellites), United, FDA, American Diabetes Association, NYSE, Safety, Pharmaceutical industry, Health insurance, Medical device

The Medicare program has expanded access to continuous glucose monitoring systems like the FreeStyle Libre 2 system and the FreeStyle Libre 14 day system for insulin-using1 Medicare beneficiaries with diabetes, removing the prior requirement of multiple daily insulin injections

Key Points: 
  • The Medicare program has expanded access to continuous glucose monitoring systems like the FreeStyle Libre 2 system and the FreeStyle Libre 14 day system for insulin-using1 Medicare beneficiaries with diabetes, removing the prior requirement of multiple daily insulin injections
    ABBOTT PARK, Ill., April 17, 2023 /PRNewswire/ -- More Medicare beneficiaries than ever before who are living with diabetes and use insulin1 will now be eligible for reimbursement when using Abbott's (NYSE: ABT) FreeStyle Libre® portfolio3,4 – the most prescribed and affordable continuous glucose monitoring system (CGM) in the United States.
  • "We've been focused on highlighting the tremendous benefits of continuous glucose monitoring to help people living with diabetes manage their care easily and pain-free.
  • Increasing access is a monumental step by Medicare to allow more people to have access to FreeStyle Libre so they can spend less time worrying and more time living healthier, better lives."
  • FreeStyle Libre 2 and FreeStyle Libre 3 systems: Failure to use FreeStyle Libre 2 or FreeStyle Libre 3 systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury.

FDA Clears Reader for Abbott's FreeStyle Libre® 3 System

Retrieved on: 
Friday, April 14, 2023
Diabetes, FreeStyle, USB, Quality of life, Continuous glucose monitor, Medicare, GlySens ICGM, Health, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Food, Safety, Medical device

ABBOTT PARK, Ill., April 14, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared a reader for its FreeStyle Libre® 3 integrated continuous glucose monitoring (iCGM) system, which features the world's smallest, thinnest and most discreet5 glucose sensor.

Key Points: 
  • ABBOTT PARK, Ill., April 14, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared a reader for its FreeStyle Libre® 3 integrated continuous glucose monitoring (iCGM) system, which features the world's smallest, thinnest and most discreet5 glucose sensor.
  • "The FreeStyle 3 reader provides more choice to people living with diabetes to have access to lifesaving technology that is smaller and easier to use and comes without the high-cost burdens of other systems."
  • The reader uses a rechargeable lithium-ion battery, which is commonly found in many other electronic devices like mobile phones.
  • The user manual for the FreeStyle Libre 3 reader provides details on how to safely store, charge and use the device, including always using the Abbott-provided USB cable and power adapter.

Self-Testing Global Market Report 2023: Rising Approval and Product Launches Boosts $20.4 Billion Industry - ResearchAndMarkets.com

Retrieved on: 
Friday, April 7, 2023
Medical Supplies, Health, Sample, Telehealth, US Foods, Power-on self-test, Diabetes, FreeStyle, Urine, Smartphone, Abbott, Cholesterol, Food, COVID-19, Woman, Sleep apnea, Research, USD, Person, Withings, Projection, Blood, Patient, Fertility, HCG, Deep Ellum, Dallas, Region, Heart rate, FDA, Glycated hemoglobin, Software, Beauty salon, Pharmaceutical industry, Medical device, Application

The "Self-Testing Market by Product, Sample, Application and by Region - Global Forecast to 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Self-Testing Market by Product, Sample, Application and by Region - Global Forecast to 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • Furthermore, rising approval and product launches in self-testing market are other factors supporting the market growth.
  • Rising approval and product launch is anticipated to fuel the market growth during the forecast period.
  • Increasing the use of modern technology and expanding the healthcare infrastructure is predicted to spur the market growth during the projected period.

This Week in Health News: 11 Stories You Need to See

Retrieved on: 
Friday, March 10, 2023
Science, AID, Peptic ulcer disease, Planet Fitness, FreeStyle, Digital, Insulin, Nutricia North America, Food, AI, Danone, Motivation, Bureau of Oceans and International Environmental and Scientific Affairs, Use, ChatGPT, Medical device

NEW YORK, March 10, 2023 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists covering the healthcare industry stay on top of the week's most newsworthy and popular releases, here's a roundup of stories from the week that shouldn't be missed.

Key Points: 
  • The groundbreaking event, which takes place March 11 and March 12, will examine the science and storytelling around women's whole health.
  • Attendees will hear from experts and thought leaders, including Katie Couric, Maria Shriver, Christy Turlington Burns, Dr. Laurie Santos, Phoebe Robinson, Judy Greer, Dr. Piraye Yurttas Beim, Emma Lovewell, Jessi Miley-Dyer, and Jamie Wheal.
  • Health App Uses ChatGPT to Replace Human Health Coaches The AI coach provides instant answers to user questions, offers guidance and motivation, and helps them achieve their weight goals.
  • It can be customized to meet individual needs, allowing users to tailor their experience to their unique situation.

U.S. FDA Clears Abbott's FreeStyle Libre® 2 and FreeStyle Libre® 3 Sensors for Integration with Automated Insulin Delivery Systems

Retrieved on: 
Monday, March 6, 2023
Insulin, NYSE, Tandem, Loop, Woman, Regulation of tobacco by the U.S. Food and Drug Administration, GlySens ICGM, FreeStyle, Food, Continuous glucose monitor, Diabetes, FDA, United, AID, CGM, Medical device, Dietary supplement, Fine chemical, Pharmaceutical industry, Pharmaceutical industry in Switzerland

AID systems help people manage daily diabetes care by automatically adjusting and administering the insulin delivered by an insulin pump based on real-time glucose data from their FreeStyle Libre 2 or FreeStyle Libre 3 sensors.

Key Points: 
  • AID systems help people manage daily diabetes care by automatically adjusting and administering the insulin delivered by an insulin pump based on real-time glucose data from their FreeStyle Libre 2 or FreeStyle Libre 3 sensors.
  • Abbott is working with leading insulin pump manufacturers to integrate their systems with the FreeStyle Libre 2 and FreeStyle Libre 3 sensors as soon as possible.
  • The modified FreeStyle Libre 2 and FreeStyle Libre 3 sensors will be available in the U.S. later this year.
  • Over time, the modified sensors will replace the current FreeStyle Libre 2 and FreeStyle Libre 3 sensors available today in the U.S.